Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) CFO Molly Henderson sold 3,435 shares of the company's stock in a transaction on Monday, April 8th. The stock was sold at an average price of $11.10, for a total transaction of $38,128.50. Following the completion of the sale, the chief financial officer now owns 95,263 shares of the company's stock, valued at $1,057,419.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Molly Henderson also recently made the following trade(s):
- On Friday, January 19th, Molly Henderson sold 6,307 shares of Phathom Pharmaceuticals stock. The stock was sold at an average price of $7.75, for a total transaction of $48,879.25.
Phathom Pharmaceuticals Trading Down 2.1 %
Shares of NASDAQ:PHAT opened at $11.80 on Thursday. The stock has a market capitalization of $690.06 million, a PE ratio of -3.04 and a beta of 0.63. Phathom Pharmaceuticals, Inc. has a 1 year low of $6.07 and a 1 year high of $17.02. The firm has a fifty day moving average price of $9.24 and a 200 day moving average price of $8.76.
Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report) last released its quarterly earnings results on Thursday, March 7th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.92) by $0.12. The firm had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.93 million. During the same quarter last year, the company earned ($1.33) earnings per share. On average, sell-side analysts forecast that Phathom Pharmaceuticals, Inc. will post -4.22 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Phathom Pharmaceuticals
Charles Payne’s Gift to Stock Investors
From Unstoppable Prosperity | Ad
Right now, millions of good honest folks are feeling the squeeze.
Last year's terrible market did a number on their accounts.
Stock values plunged.
Retirement accounts lost too.
Watch Insider's Advantage Event Tuesday at 4:00 PM ET
A number of hedge funds have recently bought and sold shares of PHAT. Decheng Capital LLC bought a new stake in Phathom Pharmaceuticals during the fourth quarter valued at about $7,760,000. Catalys Pacific LLC bought a new stake in Phathom Pharmaceuticals during the fourth quarter valued at about $6,592,000. Woodline Partners LP bought a new stake in Phathom Pharmaceuticals during the second quarter valued at about $9,647,000. BlackRock Inc. boosted its holdings in Phathom Pharmaceuticals by 22.6% during the second quarter. BlackRock Inc. now owns 2,002,632 shares of the company's stock valued at $28,678,000 after acquiring an additional 369,722 shares during the period. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in Phathom Pharmaceuticals by 296.8% during the third quarter. Jacobs Levy Equity Management Inc. now owns 280,932 shares of the company's stock valued at $2,913,000 after acquiring an additional 210,129 shares during the period. 99.01% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Separately, Needham & Company LLC reiterated a "buy" rating and issued a $26.00 price objective on shares of Phathom Pharmaceuticals in a report on Monday, April 1st.
View Our Latest Analysis on Phathom Pharmaceuticals
Phathom Pharmaceuticals Company Profile
(
Get Free Report)
Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
